PALO ALTO, Calif., Sept. 14, 2020 /PRNewswire/ -- Varian (NYSE:
VAR) today announced the following leadership appointments,
effective October 5, 2020:
- Chris Toth, Varian Oncology
Systems President, has been appointed to the newly created role of
President and Chief Operating Officer;
- Kevin O'Reilly, Senior Vice
President of Global Operations, will succeed Toth as Senior Vice
President and President of Varian Oncology Systems; and
- Stephanie Foster, Vice President
of Revenue Operations, has been named Senior Vice President of
Global Supply Chain Operations.
As President and COO, Toth will oversee Varian's business
operations, including execution of the Company's fiscal 2021 goals
and strategic initiatives. Toth will continue to report to Chief
Executive Officer Dow Wilson. In addition, O'Reilly will be focused
on executing Varian's proven strategy in Oncology Systems, and
Foster will lead all aspects of the Company's integrated supply
chain for Oncology Systems.
"This announcement is a testament to the deep and diverse bench
of talented leaders we have at Varian, as well as a reflection of
our commitment to realizing our vision and strengthening our
support for Varian's customers and their patients," said Wilson.
"I'm thrilled to congratulate Chris, Kevin and Stephanie on their
expanded leadership roles, and I'm confident that they will ensure
our entire team is well positioned to build on Varian's success and
accomplish our goals for 2021 and beyond."
Wilson continued, "Chris is an ideal fit for Varian's President
and COO, as he is a proven leader whose contributions over the past
two decades have been invaluable to the growth of our company –
from both a business perspective and a cultural one. In addition to
an impressive track record of strategic planning and execution,
Chris brings a passion to his work that inspires and motivates our
team to advance the fight against cancer. I'm excited to see all
that Varian will accomplish under his leadership."
"This is an important moment in Varian's history, and I am
honored to work with our talented and agile team to build on our
strong momentum," said Toth. "Varian is moving at full speed to
achieve our goal of a world without fear of cancer. While we work
toward completing a transformational combination with Siemens
Healthineers, we're continuing to make impressive progress on our
efforts to provide more intelligent solutions, data and insights to
deliver world-class cancer care globally. Looking ahead, we don't
intend to slow down. Our unwavering focus on helping our customers
care for their patients will continue to propel us forward."
About Chris
Toth
Chris Toth is an
established leader with nearly 20 years of industry experience.
Since joining Varian in 2001, he has held multiple executive
positions. Most recently, Toth has served as President of Varian
Oncology Systems, managing more than $3
billion in revenue and over 7,000 employees worldwide. In
this role, he helped return Varian to double-digit growth. Prior to
his role as President of Varian Oncology Systems, Toth served as
President of Global Commercial and Field Operations, where he was
responsible for a global sales strategy and execution across
Varian's Oncology and Proton Therapy businesses. Under his
leadership, Varian grew its global market share and the Company's
Net Promoter Score reached all-time highs.
About Kevin
O'Reilly
Kevin
O'Reilly is a global executive with over 30 years of
experience across multiple industries and geographies. He currently
serves as Varian's SVP of Global Operations, overseeing Varian
Oncology Systems' global supply chain, revenue and customer
support, and managing $3 billion in
revenue and over 2,000 employees worldwide. Previously, O'Reilly
was President of Asia Pacific,
where he tripled Varian's Net Promoter Score and increased revenues
and orders faster than the market. Prior to joining Varian in 2009,
he held executive positions at RPO, Inc. and Photon
Dynamics.
About Stephanie
Foster
Stephanie
Foster has over 30 years of experience in supply chain,
operations and manufacturing in highly complex, regulated
industries. In her current role as Vice President of Revenue
Operations, Foster oversees contracts, sales and operation
planning, logistics, installation services and environmental health
and safety. Prior to joining Varian in 2019, she served as Vice
President of Supply Chain at Honeywell, where she managed
operations for a $4 billion division
that manufactured products for the Defense, Space and Aviation
industries. Before joining Honeywell, Foster held executive roles
at Orbital ATK and Raytheon.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow @VarianMedSys
on Twitter.
Forward-Looking Statements
Except for historical
information, this communication contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Statements concerning Varian's future orders and the
anticipated impact of the COVID-19 pandemic on Varian's business;
and any statements using the terms "could," "believe," "expect,"
"promising," "outlook," "should," "well-positioned," "will" or
similar statements are forward-looking statements that involve
risks and uncertainties that could cause Varian's actual results to
differ materially from those anticipated. Such risks and
uncertainties include: (1) the future impact of the COVID-19
pandemic on Varian's business, including but not limited to, the
impact on its workforce, operations, supply chain, demand for
products and services, and Varian's financial results and
condition; (2) Varian's ability to successfully manage the
challenges associated with the COVID-19 pandemic; (3) Varian's
ability to achieve expected synergies from acquisitions; (4) risks
associated with integrating recent acquisitions; (5) global
economic conditions and changes to trends for cancer treatment
regionally; (6) currency exchange rates and tax rates; (7) the
impact of the Tax Cuts and Jobs Act; (8) the impact of the
Affordable Health Care for America Act (including excise taxes on
medical devices) and any further healthcare reforms (including
changes to Medicare and Medicaid), and/or changes in third-party
reimbursement levels; (9) recent and potential future tariffs or a
global trade war; (10) demand for and delays in delivery of
Varian's products; (11) Varian's ability to develop, commercialize
and deploy new products; (12) Varian's ability to meet Food and
Drug Administration (FDA) and other regulatory requirements,
regulations or procedures; (13) changes in regulatory environments;
(14) risks associated with Varian providing financing for the
construction and start-up operations of particle therapy centers,
challenges associated with commercializing Varian's Proton
Solutions business; (15) challenges to public tender awards and the
loss of such awards or other orders; (16) the effect of adverse
publicity; (17) Varian's reliance on sole or limited-source
suppliers; (18) Varian's ability to maintain or increase margins;
(19) the impact of competitive products and pricing; (20) the
potential loss of key distributors or key personnel; (21)
challenges related to entering into new business lines; (22) the
occurrence of any event, change or other circumstances that could
give rise to the termination of the agreement; (23) the failure to
obtain the approval of Varian's stockholders, the failure to obtain
certain required regulatory approvals or the failure to satisfy any
of the other closing conditions to the completion of the
transaction, (24) risks related to disruption of management's
attention from Varian's ongoing business operations due to the
transaction; (25) the effect of the announcement of the transaction
on the ability of Varian to retain and hire key personnel and
maintain relationships with its customers, suppliers and others
with whom it does business, or on its operating results and
business generally; (26) the ability to meet expectations regarding
the timing and completion of the transaction; (27) risks associated
with transaction-related litigation; and (28) the other risks
listed from time to time in Varian's filings with the SEC.
For additional information concerning factors that could cause
actual results and events to differ materially from those projected
herein, please refer to Varian's Annual Report on Form 10-K for the
year ended September 27, 2019 and
subsequent Current Reports on Form 8-K and Quarterly Reports on
Form 10-Q filed with the SEC. Varian assumes no obligation to
update or revise the forward-looking statements in this
communication because of new information, future events, or
otherwise.
Varian Contacts
Investor Relations Contact
Anshul Maheshwari
Vice President, Treasury and Investor Relations
+1 (650) 424-5631
investors@varian.com
Media Contact
Kathy Conner
Vice President, Global Corporate Marketing and Communications
+1 (650) 424-5695
kathy.conner@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-announces-appointment-of-chris-toth-as-president-and-chief-operating-officer-301129827.html
SOURCE Varian